1. Fertility preservation in an oncology patient who presented with positive human chorionic gonadotropin
- Author
-
Alexandra Aserlind, Eric Widra, Arthur W. Sagoskin, Frank E. Chang, and Olivia Carpinello
- Subjects
Infertility ,Oncology ,medicine.medical_specialty ,endocrine system ,fertility preservation ,Controlled ovarian hyperstimulation ,lcsh:RC870-923 ,lcsh:Gynecology and obstetrics ,Human chorionic gonadotropin ,Breast cancer ,Internal medicine ,medicine ,Fertility preservation ,reproductive and urinary physiology ,lcsh:RG1-991 ,Pregnancy ,business.industry ,Oocyte cryopreservation ,medicine.disease ,lcsh:Diseases of the genitourinary system. Urology ,Original Article ,Ovarian stimulation ,pregnancy ,Luteinizing hormone ,business ,hormones, hormone substitutes, and hormone antagonists - Abstract
Objective: To report the case of a woman who presented for fertility preservation before breast cancer treatment who was found to be pregnant with an undesired pregnancy. Design: Case report. Setting: Single infertility practice. Patient: A 28-year-old woman with a new diagnosis of grade 3 invasive ductal carcinoma of the breast was planning to undergo oocyte cryopreservation and was found to be pregnant with an undesired pregnancy. She underwent a medical termination at a gestational age of 5 weeks 4 days. Neither the patient nor her oncology team wished to delay treatment more than was necessary. The physician and patient decided to initiate controlled ovarian hyperstimulation (COH) before her human chorionic gonadotropin (hCG) returned to normal. Intervention(s): COH in the setting of a positive quantitative hCG. Main Outcome Measure(s): Number of metaphase II (MII) oocytes cryopreserved; doses of Gonal-F and Menopur; serum E2, follicle-stimulating hormone, luteinizing hormone, hCG levels. Result(s): COH began 7 days after passing the products of conception. Baseline labs demonstrated hCG at 222 mIU/mL, follicle-stimulating hormone at
- Published
- 2020